Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors
- Design
- Retrospective cohort · 918 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants had type 2 diabetes and were survivors of an obesity-related cancer; no BMI data are reported.
- Could weight loss explain it?
- PossiblyNo weight change, HbA1c or mediation analysis is reported, so the difference between semaglutide and the other GLP-1 drugs cannot be separated from weight or metabolic change; propensity matching addressed baseline differences rather than mediation.
- Study tier
- Study tier 3LOW: a single observational cohort study, which the model caps at the observational-study ceiling; it uses an active-comparator target-trial emulation with 1:1 propensity matching, but rests on 124 events in one health system's records.
- Assessment
- Version 2 · Two independent AI reviews agreed · Nov 6, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
Using one US health system's electronic records from 2016 to 2025, researchers emulated a trial in adults who had survived an obesity-related cancer and had type 2 diabetes, matching 459 who started semaglutide with 459 who started another GLP-1 receptor agonist. Over five years 124 heart attacks, strokes or deaths occurred; the risk was 17.6% with semaglutide and 26.6% with the other drugs (hazard ratio 0.65, 95% CI 0.44-0.94; risk difference -7.41%). Because treatment was not randomised this is an association, and the comparison is between GLP-1 drugs rather than against no treatment.
01Findings
What the study reported
- Drugs
- Semaglutide
- Comparator
- other GLP-1 RA
- Primary outcome
- modified 3-point MACE (myocardial infarction, stroke, or all-cause mortality)
- Effect
- 5-year cumulative incidence 17.6% (95% CI, 12.3-22.9) with semaglutide versus 26.6% (95% CI, 20.7-32.6) with other GLP-1 RA; risk difference -7.41% and hazard ratio 0.65 (95% CI, 0.44-0.94); 124 events among 918 matched patients
- 95% confidence interval
- 95% CI, 0.44-0.94
- Follow-up
- 5 years (5-year cumulative incidence reported)
- Adverse events
- not reported in abstract
- Limitations
- An observational target-trial emulation in one health system's records: propensity matching cannot remove confounding by indication, both arms received GLP-1 drugs so there is no untreated comparison, and the result rests on 124 events in 918 matched patients; the authors say it warrants confirmation.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- type 2 diabetes required
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- obesity-related cancer survivors with type 2 diabetes
- Sample size
- 918
- Inclusion exclusion
- adults with obesity-related cancer and type 2 diabetes initiating semaglutide or another GLP-1 RA in PCORnet-UTSW records, 2016-2025
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 918
- Randomization
- no
- Blinding
- n/a
- Comparator
- other GLP-1 RA
- Follow up duration
- 5 years (5-year cumulative incidence reported)
- Outcome type
- hard
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- 95% confidence intervals reported; 124 modified 3-point MACE events among 918 matched patients
- Risk of bias
- not assessed
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- The authors declare no known competing financial interests or personal relationships that could have influenced the work.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[AIMS] Obesity-related cancer (ORCa) survivors are a unique population often excluded from landmark GLP-1 receptor agonist (GLP-1 RA) trials. Given their cardiovascular risks, we investigated whether semaglutide initiation, compared with other GLP-1 RA, was associated with modified 3-point major adverse cardiovascular events (MACE) among ORCa survivors with type 2 diabetes (T2D). [METHODS] We emulated a target trial using PCORnet-UTSW electronic health records (2016-2025). Adults with ORCa and T2D initiating semaglutide versus other GLP-1 RA were included. The primary outcome was modified 3-point MACE (myocardial infarction, stroke, or all-cause mortality). Cumulative incidence risk (CIR), risk difference (RD), and hazard ratio (HR) were estimated in 1:1 propensity score-matched cohort. [RESULTS] Among 918 matched patients (semaglutide, n = 459; other GLP-1 RA, n = 459), 124 modified 3-point MACE occurred. The 5-year CIR% was 17.6 (95% CI, 12.3-22.9) for semaglutide and 26.6 (95% CI, 20.7-32.6) for other GLP-1 RA. Semaglutide was associated with lower modified 3-point MACE risk (RD%, -7.41 [95% CI, -11.83 to - 2.98];HR, 0.65 [95% CI, 0.44-0.94]) than other GLP-1 RA. Findings were largely consistent across high-risk subgroups. [CONCLUSIONS] Semaglutide was associated with a lower modified 3-point MACE risk than other GLP-1 RA. These findings suggest potential heterogeneity in cardioprotective effects and warrant confirmation.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Nov 1, 2026 | 42956842 first ingestion |
| pubmed | Nov 1, 2026 | 42956842 duplicate matched on doi |
| pubmed | Nov 1, 2026 | 42956842 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |
| pubmed | Nov 8, 2026 | 42956842 duplicate matched on doi |
| pubmed | Nov 8, 2026 | 42956842 duplicate matched on doi |
| pubmed | Nov 8, 2026 | 42956842 duplicate matched on doi |